May have antimicrobial properties, like most ant linear peptides (Probable). In addition, when tested in vitro on the parasite Trypanosoma cruzi (responsible of the Chagas disease), is able to potently reduce the number of the three forms (epimastigote, trypomastigote and amastigote) by inducing cell death through necrosis (PubMed:28976889). May have antimicrobial properties, like most ant linear peptides (Probable). In addition, when tested in vitro on the parasite Trypanosoma cruzi (responsible of the Chagas disease), is able to moderately reduce the number of the forms epimastigote and trypomastigote. Its activity on the amastigote form has not been tested (PubMed:28976889). May have antimicrobial properties, like most ant linear peptides (Probable). In addition, when tested in vitro on the parasite Trypanosoma cruzi (responsible of the Chagas disease), shows only a weak reduction of the number of the trypomastigote forms. Has no activity on the epimastigote forms. Its activity on the amastigote form has not been tested (PubMed:28976889). Expressed by the venom gland. Promising drug candidate or lead for the development of new drugs to treat Chagas disease (also called American Trypanosomiasis). Shows a high selectivity index (SI) of 80 to the trypomastigote forms. Belongs to the non-disulfide-bridged peptide (NDBP) superfamily. Medium-length antimicrobial peptide (group 3) family. Ponericin-W subfamily. It is not indicated if M-poneratoxin-Dq3b and M-poneratoxin-Dq3c have been predicted from the transcriptome or found as mature peptides in the peptidome. Authors indicate they have been cleaved from M-poneratoxin-Dq3a and amidated.